A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.
Many approaches for treating hemophilia via gene transfer have been attempted in large animal models but all have potential drawbacks. Recombinant adenoviral vectors offer high-efficiency transfer of an episomal vector but have been plagued by the cytotoxicity/immunogenicity of early-generation vectors that contain viral genes. In our current study, we have used a nonintegrating helper-dependent (HD) adenoviral vector for liver-directed gene transfer to achieve hemostatic correction in a dog with hemophilia B. We measured plasma canine factor IX (cFIX) concentrations at a therapeutic range for up to 2.5 months and normalization of the whole blood clotting time (WBCT) for about a month. This was followed by a decrease and stabilized partial correction for 4.5 months. Hepatic gene transfer of a slightly lower dose of the HD vector resulted in WBCTs that were close to normal for 2 weeks, suggesting a dose threshold effect in dogs. In sharp contrast to other studies using first- or second-generation adenoviral vectors, we observed no vector-related elevation of liver enzymes, no fall in platelet counts, and normal liver histology. Taken together, this study demonstrates that injection of an adenoviral HD vector results in complete but transient phenotypic correction of FIX deficiency in canine models with no detectable toxicity.
Ehrhardt
Anja
A
Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA, USA.
Xu
Hui
H
Dillow
Aaron M
AM
Bellinger
Dwight A
DA
Nichols
Timothy C
TC
Kay
Mark A
MA
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D004274:DNA, Recombinant; D004285:Dogs; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000633:toxicity; D002836:Hemophilia B / Q000235:genetics / Q000628:therapy*; D008099:Liver / Q000166:cytology / Q000502:physiology*; D020125:Mutation, Missense; D010641:Phenotype; D013921:Thrombocytopenia / Q000517:prevention & control
D004274:DNA, Recombinant